APO-NEVIRAPINE XR 400 MG — DIN 02427931
NEVIRAPINE : 400 MG · APOTEX INC · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is APO-NEVIRAPINE XR?
APO-NEVIRAPINE XR 400 MG contains NEVIRAPINE : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02427931, held by APOTEX INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 17-Apr-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is APO-NEVIRAPINE XR used for?
Treatment of HIV-1 infection in combination with other antiretroviral agents. Not for monotherapy. Use depends on CD4 counts and risk of toxicity.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Nevirapine cost around the world?
Nevirapine is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 18 | 19 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 5 | EUR███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Morocco | PPV (public price) | 2 | 3 | MAD███.██ |
| United States | acquisition | 1 | 3 | USD███.██ |
| Australia | ex-manufacturer | 2 | 2 | AUD███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
39 pack listings across 34 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Nevirapine pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Nevirapine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Nevirapine, across 8 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 1 | 1 | AURO-NEVIRAPINE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP NEVIRAPINE | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 1 | 1 | MYLAN-NEVIRAPINE | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-NEVIRAPINE, APO-NEVIRAPINE XR | No marketed DIN |
| BOEHRINGER INGELHEIM (CANADA) LTD LTEE | 2 | 0 | VIRAMUNE, VIRAMUNE XR | No marketed DIN |
| TEVA CANADA LIMITED | 1 | 0 | TEVA-NEVIRAPINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 400 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text (refers to Dosage Forms, Composition and Packaging section). |
| Storage | Not explicitly detailed in the provided text (refers to Storage and Stability section). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Nevirapine |
|---|---|
| ATC code | J05AG01 |
| AHFS class | 48:08.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02427931 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2427931 |
| Brand name | APO-NEVIRAPINE XR |
| Generic / active ingredient | NEVIRAPINE : 400 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | J05AG01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AG |
| Current status | CANCELLED POST MARKET |
| Status date | 17-Apr-2025 |
| Original market date | 2016-06-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Lead-in: 200 mg daily for 14 days. Maintenance: 200 mg twice daily (immediate-release) or 400 mg once daily (extended-release). Must be used in combination with other antiretrovirals.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; severe hepatic dysfunction (AST/ALT > 5X ULN); previous nevirapine-induced hepatitis or severe rash; hereditary galactose intolerance; use with St. John’s wort.
Warnings and precautions
Serious hepatotoxicity and fatal skin reactions (SJS/TEN) especially in first 18 weeks. Risk higher in women and patients with higher CD4 counts. Monitor liver function closely.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-NEVIRAPINE | 200 MG | TABLET | AURO PHARMA INC | MARKETED | 02318601 |
| JAMP NEVIRAPINE | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02405776 |
| MYLAN-NEVIRAPINE | 200 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02387727 |
| APO-NEVIRAPINE | 200 MG | TABLET | APOTEX INC | APPROVED | 02396653 |
| TEVA-NEVIRAPINE | 200 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02352893 |
| VIRAMUNE | 200 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | 02238748 |
| VIRAMUNE XR | 400 MG | TABLET (EXTENDED-RELEASE) | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | 02367289 |
2 · Same class — other molecules in ATC J05AG
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Efavirenz | AURO-EFAVIRENZ · JAMP-EFAVIRENZ · MYLAN-EFAVIRENZ · SUSTIVA 100MG · +4 more | 8 | 3 | Yes |
| Nevirapine | APO-NEVIRAPINE · APO-NEVIRAPINE XR · AURO-NEVIRAPINE · JAMP NEVIRAPINE · +4 more | 8 | 3 | Yes |
| Etravirine | INTELENCE | 3 | 2 | Yes |
| Doravirine | PIFELTRO | 1 | 1 | Yes |
| Rilpivirine | EDURANT | 1 | 1 | Yes |
| Delavirdine | RESCRIPTOR | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-NEVIRAPINE XR called?
The same molecule, Nevirapine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Cipla Nevirapine Oral Suspension | Latin | South Africa |
| NEVIPAN | Latin | Morocco |
| Adco-Nevirapine Tablets | Latin | South Africa |
| Aspen Nevirapine Suspension | Latin | South Africa |
| Cipla Nevirapine | Latin | South Africa |
| Nevasta | Latin | South Africa |
| NEVIMUNE | Latin | Morocco |
| Nevipin | Latin | Saudi Arabia |
| Nevir | Latin | South Africa |
| Nevirapine Viatris | Latin | Australia |
| Nevivir | Latin | South Africa |
| Sonke-Nevirapine Tablets | Latin | South Africa |
| Viramune | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.